Great to see!! Long duration though till Dec 2021...not sure that is ideal:
Study Type :
Interventional (Clinical Trial)
Estimated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomly allocated to receive either Aviptadil together with standard care or the placebo (NaCl 0.9%) together with standard care,
Masking:
Double (Participant, Investigator)
Masking Description:
Patients and the investigator administering inhalation devices of drug or placebo are not aware of which group they have been randomized to (double-blinded). Someone not involved in the study (e.g. the hospital pharmacist or a nurse not involved in study) prepares the inhalation devices with either drug or placebo according to the randomization plan received by the CTU
Primary Purpose:
Treatment
Official Title:
Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS: a Randomized, Placebo Controlled, Multicenter Trial
Estimated Study Start Date :
September 2020
Estimated Primary Completion Date :
December 2021
Estimated Study Completion Date :
December 2021
Market Data 
Markets 
AI
